Varian Announces CE Mark for Embozene in Genicular Artery Embolisation, Expanding Treatment for Knee Osteoarthritis

Contributed by: Business Wire

Logo

Tags

Radiology

Physical Therapy

Managed Care

Surgery

Oncology

General Health

Health

Health Technology

Varian

More Like This

Inside the Science: New White Paper Explores the Injection Set to Redefine the Treatment of Knee Osteoarthritis & Unlock Access to Non-Surgical Options for Patients on the NHS

U.S. FDA GRANTS LIPOGEMS® SECOND IDE APPROVAL FOR A CLINICAL TRIAL ON THE TREATMENT FOR KNEE OA

World’s First Patients Successfully Treated With Novel Scarcell Therapeutics Therapy Using Gum Cells Designed to Relieve Knee Osteoarthritis

Emboline, Inc. Completes Enrollment in U.S. Pivotal IDE Trial of the Emboliner® Embolic Protection Catheter Designed to Protect Patients from Embolic Injury During Transcatheter Aortic Valve Replacement

Protembis Announces FDA Approval of its Pivotal Investigational Device Exemption (IDE) Study

PK MED Announces FDA Clearance to Initiate Its Clinical Program for PKM-01, for Local Treatment of Gout Flares, Directly by a Phase 2 Trial

PR Newswire associated0

Guerbet announces an important milestone achievement in the "Vascular Embolization" indication for Lipiodol® Ultra Fluid (Iodinated ethyl esters of fatty acids of poppy seed oil)

Nanochon Announces Health Canada Approval for First in Human Investigation